EXANE DERIVATIVES: CYTK position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on CYTK, newest first. How the timeline and the estimate are built.
EXANE DERIVATIVES held 53 CYTK shares at 2022-06-30 per its 13F-HR filed 2022-07-12.
the latest 13F is the newest step
- period ended2022-06-3013F 53 sharesChange vs previous 13F 0 shares
<0.01% of the 13F portfolio, value $2,082.
13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-03-3113F 53 sharesChange vs previous 13F 0 shares
<0.01% of the 13F portfolio, value $1,951.
13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-12-3113F 53 sharesChange vs previous 13F 0 shares
<0.01% of the 13F portfolio, value $2,416.
13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-09-3013F 53 sharesChange vs previous 13F -1,589 shares
<0.01% of the 13F portfolio, value $1,894.
13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-06-3013F 1,642 sharesChange vs previous 13F 0 shares
0.01% of the 13F portfolio, value $30,852.
13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-03-3113F 1,642 sharesChange vs previous 13F 0 shares
0.01% of the 13F portfolio, value $38,191.
13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2020-12-3113F 1,642 sharesChange vs previous 13F not available
0.01% of the 13F portfolio, value $34,119.
13F-HR 0001623883-21-000002 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).